Author:
Vanacker Hélène,Bally Olivia,Kassem Loay,Tredan Olivier,Heudel Pierre,Bachelot Thomas
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine
Reference22 articles.
1. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer;Di Leo;J Clin Oncol,2010
2. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial;Di Leo;J Natl Cancer Inst,2014
3. Targeted treatments for breast cancer: a step forward;Bachelot;Lancet Oncol,2013
4. Robertson J, Llombart-Cussac A, Feltl D, Dewar J, Marek Jasiówka M, Hewson N et al. Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: overall survival from the phase II ‘first’ study. 2014 San Antonio Breast Cancer Symposium, Publication Number: S6-04.
5. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER);André;Lancet Oncol,2014
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献